FBX-301

FBX-301 is an adeno-associated virus (AAV) gene therapy candidate that was developed by Forge Biologics. Although the specific molecular target and indication were not publicly disclosed in detail, early company pipeline materials from approximately 2020 identified it as a program for a rare cancer indication, potentially in the Phase 1/2 stage of development. Forge Biologics, which has since transitioned to focus heavily on its role as a gene therapy CDMO and its lead clinical programs (such as FBX-101 for Krabbe disease), no longer lists FBX-301 on its active pipeline. This suggests the program has likely been discontinued, deprioritized, or merged into other undisclosed research efforts.